A JAMA Oncology viewpoint argues that the COVID-19 pandemic presents a prime opportunity to make clinical trial design and execution more efficient.
The cancer research community needs to filter out wasteful clinical trials and encourage research that challenges unproven practices that consume resources, three Canadian researchers argue in an opinion piece published today in JAMA Oncology about cancer research after COVID-19.
The viewpoint, titled “The Day After COVID-19 — Time to Rethink Oncology Clinical Research,” argues for a more selective approach to research that will is more likely to yield meaningful results while also husbanding resources.
Daniel Araujo, M.D., Geoffrey A. Watson, M.D., and Lillian L. Siu, M.D., all of the Princess Margaret Cancer Centre in Toronto, also discuss the possibility of a greater reliance on telemedicine, virtual tumor boards, and centralized artificial intelligence facilitating “the search for suitable clinical trials.”
“Clinical research must be leaner and more efficient,” they write. “It is time to incorporate new technologies, revisit old practices and move forward toward better outcomes for our patients.:
Here are some of the points they made:
Today, the clade 2b outbreak has reached alarming proportions, with over 94,000 confirmed cases reported across 117 countries, including significant numbers in the U.S. and Brazil, and up to 103 deaths. The virus has been found to affect younger men who have sex with men, who are linked to high rates of HIV co-infection.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.
Listen